Get the Stockscreener App
4.42
4.54%
-0.21
Clene Inc Stock (CLNN) Latest News
Clene Inc. secures additional NIH grant funds for ALS therapy - MSN
Promising Nanotechnology Stocks To Keep An Eye OnJanuary 31st - MarketBeat
Nanotechnology Stocks To Keep An Eye OnFebruary 03rd - MarketBeat
Nanotechnology Stocks To Follow NowFebruary 01st - MarketBeat
Best Nanotechnology Stocks To Follow TodayJanuary 30th - MarketBeat
Clene Inc. secures additional NIH grant funds for ALS therapy By Investing.com - Investing.com UK
Clene files to sell 1.15M shares of common stock by selling shareholders - MSN
Clene (CLNN) Stock Price, News & Analysis - MarketBeat
IBN Coverage: Clene (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALS - Nasdaq
Clene Secures $10 Million Debt Facility to Advance ALS Drug Development - Citybuzz
Clene (NASDAQ: CLNN) Paves Cash Runway To Advance CNM-Au8(R) For ALS - Barchart
3 US Growth Stocks With High Insider Ownership - Yahoo Finance
IBN Coverage: Clene (NASDAQ: CLNN) Receives FDA Roadmap on Potential Accelerated Pathway for CNM-Au8(R) - Yahoo Finance
Clene Receives FDA Guidance on Potential Accelerated Approval Pathway for ALS Drug CNM-Au8 - Citybuzz
Clene (NASDAQ: CLNN) Receives FDA Roadmap on Potential Accelerated Pathway for CNM-Au8(R) - The Globe and Mail
Clene Secures $10M Debt Facility to Enhance Position - TipRanks
Clene Secures $10 Million Debt Facility to Advance ALS and Neurodegenerative Disease Treatments - Citybuzz
IBN Coverage: Clene (NASDAQ: CLNN) Secures $10M Debt Facility to Advance Neurodegenerative Disease Treatments - Yahoo Finance
Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan - The Manila Times
Real-World Evidence Helps Open Accelerated Approval Pathway For Neurodegeneration Therapies - News & Insights
Clene Inc. Provides Update on Corporate Presentation and ALS Clinical Trials - Defense World
IBN Coverage: Clene (NASDAQ: CLNN) Advances CNM-Au8 in ALS With FDA Guidance on Accelerated Approval Pathway - Yahoo Finance
FDA outlines steps to consider accelerated approval of CNM-Au8 - ALS News Today
Clene Receives FDA Guidance on Accelerated Approval Path for ALS Treatment CNM-Au8 - Citybuzz
Clene Gains FDA Support for ALS Treatment Approval - TipRanks
FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS - The Manila Times
FDA Opens Accelerated Approval Path for Clene's Breakthrough ALS Treatment After 78% Survival Benefit - StockTitan
Clene (NASDAQ:CLNN) Given New $84.00 Price Target at Benchmark - Defense World
Clene shares hold Buy rating as analyst sees FDA decision impacting time to market - Investing.com
Roth Capital Has Bearish Forecast for Clene FY2024 Earnings - Defense World
Clene (NASDAQ:CLNN) Price Target Lowered to $83.00 at Canaccord Genuity Group - Defense World
HC Wainwright Reaffirms Buy Rating for Clene (NASDAQ:CLNN) - Defense World
AWM Investment Company, Inc. Expands Stake in Clene Inc - GuruFocus.com
Clene price target lowered to $83 from $86 at Canaccord - Yahoo Finance
ARMISTICE CAPITAL, LLC Acquires New Stake in Clene Inc - GuruFocus.com
Certain Warrants of Clene Inc. are subject to a Lock-Up Agreement Ending on 15-NOV-2024. - Marketscreener.com
Clene Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Canaccord cuts Clene stock target, holds buy rating on FDA meeting - Investing.com UK
Clene Inc (CLNN) Q3 2024 Earnings: EPS of -$1.22 Beats Estimates, Revenue at $0.087 Million Misses Expectations - GuruFocus.com
Clene Inc. (CLNN) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Clene Announces Q3 2024 Results and ALS Drug Progress - TipRanks
Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights - The Manila Times
(CLNN) Technical Data - Stock Traders Daily
Clene to Meet with FDA Leadership to Discuss CNM-Au8 Biomarker for ALS Treatment - Vancity Buzz
IBN Coverage: Clene (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker With FDA Leadership - Yahoo Finance
Clene Unveils Phase 3 Trial Design at NEALS - TipRanks
Clene Showcases Progress on CNM-Au8 for Neurodegenerative Diseases at Investor Conferences - Vancity Buzz
IBN Coverage: Clene (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates at Investor Conferences - Yahoo Finance
Clene Inc (CLNN-Q) QuotePress Release - The Globe and Mail
(CLNN) Trading Report - Stock Traders Daily
IBN Coverage: Clene (NASDAQ: CLNN) Closes $7.3M Registered Direct Offering and Concurrent Private Placements - Yahoo Finance
Clene Secures $7.3M in Funding to Advance Neurodegenerative Disease Treatment - Vancity Buzz
0.99%
0.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):